General Biotechnology

Most “prior art” searches miss the real fight.
If you’ve ever watched a patentability dispute hinge on a single phrase—one keyword, one claim element, one citation—you already know the problem: the search is often only as good as the language you’re lo…

The Biosimilar Patent Dance Isn’t a Game of Luck—It’s a Game of Timing, Leverage, and Narrative.
If you’re a biologics innovator or a biosimilar applicant, you already know the headline: the “patent dance” can decide years of market access. But the rea…

Generic drug makers are supposed to be the industry’s steady engine—lower prices, broader access, and predictable margins. But the reality is messier. According to DrugPatentWatch’s latest analysis, a growing list of forces is squeezing generic pharma …

Biopharma is hiring for “innovation,” but too many teams still build IP like it’s an afterthought.
Here’s the problem: when IP portfolios are treated as standalone assets—rather than as a living map of how a company actually organizes work—recruiting b…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after you’ve licensed, invested, hired counsel, and filed. But in pharma, the real cost often…

Most teams look at patents the wrong way.
They read claims like a verdict—either you’re “in” or you’re “out.” But formulation patents rarely work like that. In practice, they’re more like a map of constraints: what a competitor can’t do, what they mi…

Pharma pipelines don’t fail because of science. They fail because of freedom-to-operate.
That’s the uncomfortable truth many teams learn too late: a brilliant molecule can still get stuck—or worse, blocked—by patents, exclusivities, and licensing lan…

Drug patent strategy is having a moment—and it’s not the one most teams are planning for.
For years, “portfolio value” has been treated like a spreadsheet exercise: count patents, map expiration dates, assign a probability of grant, and move on. But th…

Generic launches aren’t “surprises”—they’re signals. The edge is knowing how to read them.
Most teams treat generic forecasting like a spreadsheet exercise: pull a few patent expirations, add a buffer, and hope the market agrees. But in branded pharma,…

Big Pharma doesn’t just “feel” a patent cliff—it signals it.
And one of the most overlooked signals isn’t in earnings calls or press releases. It’s in the hiring patterns that follow major patent expirations—especially the quiet, operational reshufflin…